Examining the effect of the small molecule on BACE1 and LAMP1 accumulation in dystrophic axons as well as on amyloid plaque pathology could shed more light on the contribution of these pathways to AD pathogenesis and the therapeutic potential of manipulating AP-4-dependent pathways in AD treatment. The gene discussed is BACE1; the disease is Alzheimer disease.